불응성 염증성 근병증 환자에 대한 Rituximab 치료 = Rituximab Treatment for the Patients with Refractory Inflammatory Myopathy

다국어 초록 (Multilingual Abstract)

Objective. To assess the efficacy and safety of rituximab (RTX) on disease activity and muscle strength in patients with inflammatory myopathies refractory to conventional therapy. Methods. Four inflammatory myopathy patients who had been refractory to glucocorticoids, one or more immunosuppressive therapies and intravenous immunoglobulin were treated on an open-label basis. Each patient received two 500 mg doses of RTX 2 weeks apart in one cycle. In one patient who did not respond after the first cycle of RTX, the infusion schedule was modified by the physician. We measured muscle enzyme including CPK, LDH and assessed muscle strength individually to evaluate RTX response. Additionally anti-CD19 antibody was measured. Results. Three patients responded to the first cycle of RTX treatment with improvements in muscle enzyme and muscle strength, and then maintained physical function over the duration of several infusion cycles. In one patient, muscle enzyme did not decrease after the first cycle of RTX, and a high dose glucocorticoid was given. After modifying the treatment schedule with monthly RTX infusion, his muscle enzyme level and muscle strength improved. Anti-CD19 antibody decreased after RTX generally, but responses were variable. Herpes zoster infection occurred in two patients. Conclusion. Rituximab may be a therapeutic choice in refractory inflammatory myopathy. However a further trial is needed to confirm the efficacy and prove the safety.

참고문헌 (Reference)

1 Majmudar S, "Treatment of adult inflammatory myositis with rituximab: an emerging therapy for refractory patients" 15 : 338-340, 2009

2 Hainsworth JD, "Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis" 5 (5): S12-S16, 2003

3 Mahler EA, "Rituximab treatment in patients with refractory inflammatory myopathies" 50 : 2206-2213, 2011

4 Valiyil R, "Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series" 62 : 1328-1334, 2010

5 Chiappetta N, "Rituximab in the treatment of refractory dermatomyositis" 11 : 264-266, 2005

6 Levine TD, "Rituximab in the treatment of dermatomyositis: an open-label pilot study" 52 : 601-607, 2005

7 Rios Fernández R, "Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature" 27 : 1009-1016, 2009

8 Cooper MA, "Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients" 56 : 3107-3111, 2007

9 Oddis CV, "RIM Study Group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial" 65 : 314-324, 2013

10 Cohen SB, "REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks" 54 : 2793-2806, 2006

11 Whelan BR, "Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion" 48 : 594-595, 2009

12 Bohan A, "Polymyositis and dermatomyositis (second of two parts)" 292 : 403-407, 1975

13 Chiu YE, "Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use" 28 : 357-367, 2011

14 Ernste FC, "Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations" 88 : 83-105, 2013

15 Pipitone N, "Established and new treatments of the idiopathic inflammatory myopathies: dermatomyositis and polymyositis" 25 : 896-906, 2007

16 Edwards JC, "Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis" 350 : 2572-2581, 2004

17 Reff ME, "Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20" 83 : 435-445, 1994

18 Rider LG, "Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies" 305 : 183-190, 2011

19 Emery P, "DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial" 54 : 1390-1400, 2006

20 Bader-Meunier B, "Club Rhumatismes et Inflammation. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry" 38 : 1436-1440, 2011

21 Sultan SM, "Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy" 26 : 887-893, 2008

22 Rosman Z, "Biologic therapy for autoimmune diseases: an update" 11 : 88-, 2013

23 Chambers SA, "Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases" 14 : 210-214, 2005